Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 20.8%

Iterum Therapeutics plc (NASDAQ:ITRM) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 1,790,000 shares, a decrease of 20.8% from the December 15th total of 2,260,000 shares. Based on an average daily trading volume, of 2,880,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 6.7% of the company’s stock are sold short.

Iterum Therapeutics Stock Down 3.8 %

ITRM stock traded down $0.06 during midday trading on Thursday, hitting $1.54. The company’s stock had a trading volume of 607,567 shares, compared to its average volume of 598,002. The firm has a 50-day simple moving average of $1.85 and a 200-day simple moving average of $1.41. The firm has a market capitalization of $42.38 million, a P/E ratio of -0.77 and a beta of 2.33. Iterum Therapeutics has a 52-week low of $0.81 and a 52-week high of $3.02.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Iterum Therapeutics stock. XTX Topco Ltd purchased a new stake in Iterum Therapeutics plc (NASDAQ:ITRM) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned approximately 0.15% of Iterum Therapeutics at the end of the most recent reporting period. 9.21% of the stock is owned by institutional investors and hedge funds.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.